T
TransCode Therapeutics
Delivering on the promise of RNAi therapeutics to defeat cancer
About TransCode Therapeutics
TransCode Therapeutics, based in Boston, is a biotechnology company focused on oncology. The company is dedicated to developing innovative therapies aimed at eradicating metastatic tumor cells, which are cancer cells that have spread from the primary tumor to other parts of the body. TransCode's investigational platform includes therapeutic candidates like TTX MC138 and diagnostics, which are currently in development and have not yet been evaluated by the FDA or any other regulatory agency. The company's approach targets the genetic markers that drive cancer onset, progression, and recurrence, aiming to deliver these therapies directly to the cells and tissues of interest while minimizing side effects in other tissues. TransCode operates in the biotechnology and pharmaceutical market, primarily serving cancer patients and healthcare providers. The business model revolves around research and development of cancer therapies, with revenue generated through partnerships, clinical trials, and future commercialization of their products.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2016
- Headquarters
- Boston, United States
- Listing
- IPO 2021
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 76.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Oct 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Apr 2026 | $0 | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Oct 2025 | $25M | — | Ck-lifesciences | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for TransCode Therapeutics is 2K monthly website visits, down 4.8% over the last three months. TransCode Therapeutics's team declined 5.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
National Institutes of Health
Small Business Innovation Research
National Cancer Institute (NCI)
Series B and later1 investor entered at this stage
Ck-lifesciences
Other known investors5 additional known investors
Harvard Medical School
Massachusetts General Hospital
Michigan State University Research Foundation
Red Cedar Ventures
TRITON FUNDS
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about TransCode Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TransCode Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.